- Home
- JFR vs APMD Comparison
JFR vs APMD Comparison
Compare JFR & APMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JFR | APMD |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | N/A | 2026 |
Fundamental Metrics
Financial Performance| Metric | JFR | APMD |
|---|---|---|
| Price | $7.47 | $29.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 610.6K | 321.0K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 11.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.16 | $20.02 |
| 52 Week High | $8.24 | $35.29 |
Technical Indicators
Market Signals| Indicator | JFR | APMD |
|---|---|---|
| Relative Strength Index (RSI) | 36.68 | 55.98 |
| Support Level | $7.46 | $25.16 |
| Resistance Level | $7.60 | $29.71 |
| Average True Range (ATR) | 0.07 | 2.10 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 9.62 | 72.31 |
Price Performance
Historical ComparisonAbout JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests a majority of its managed assets in secured Senior Loans and unsecured Senior Loans, with an average duration of one year or less, in which unsecured Senior Loans will be, at the time of investment, investment grade quality.
About APMD Apnimed Inc. Common Stock
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).